Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. The company is headquartered in Alpharetta, Georgia and currently employs 159 full-time employees. The company went IPO on 2010-04-22. The company is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. ILUVIEN is an intravitreal implant that treats patients by delivering a continuous micro dose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. ILUVIEN is inserted into the back of the patient's eye in a non-surgical procedure employing a device with a 25-gauge needle, which allows for a self-sealing wound. DME is also treated by laser photocoagulation, a retinal procedure in which a laser is used to apply a burn.

Industry: Pharmaceutical Preparations Peers: Item 9 Labs Corp. Cognition Therapeutics Inc Hepion Pharmaceuticals Inc Cumberland Pharmaceuticals Inc Elite Pharmaceuticals Inc Johnson & Johnson Lipocine Inc NVN Liquidation, Inc. Reviva Pharmaceuticals Holdings Inc Zynerba Pharmaceuticals, Inc.